Physician profile
Brent Ogle
NPI 1689606451
$10,054.25
in general payments reported to CMS, 2019-2025
46 companies · $1,641 in 2025
The $1,641 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,360 · 2020: $1,103 · 2021: $1,501 · 2022: $1,289 · 2023: $1,308 · 2024: $1,853 · 2025: $1,641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,801.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,230.30 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,106.21 | 2020-2025 | |
| Pfizer INC. | $1,051.96 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $894.92 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $666.79 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Currax Pharmaceuticals LLC | $435.42 | 2020-2025 | Contrave, Nexletol, Nexlizet |
| Janssen Pharmaceuticals, INC | $412.68 | 2019-2024 | Spravato |
| Amgen INC. | $365.02 | 2019-2025 | Otezla, Repatha, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $361.15 | 2019-2024 | Trulance, Xifaxan |
| Lilly USA, LLC | $355.38 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $339.14 | 2019-2025 | Gardasil 9, Capvaxive |
| Kowa Pharmaceuticals America, INC. | $246.77 | 2019-2023 | Livalo |
| Amarin Pharma, INC. | $233.55 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.42 | 2019-2023 | Jardiance |
| Allergan, INC. | $181.78 | 2019-2020 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brent Ogle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.